White Paper

P.E.R.F.E.C.T. the Packaging Selection Process

A practical, step-by-step framework for navigating the full complexity of injectable drug packaging component selection — from particulate control and E&L risk to CCI validation and fill/finish compatibility.

Status Published

Format White Paper

Language English

Access Registration Required

Access the White Paper

Resource Overview

About this White Paper

Injectable drug packaging failures can compromise patient safety, trigger regulatory action, and damage brand trust for years — making informed component selection a business-critical discipline. Datwyler's P.E.R.F.E.C.T. framework provides a structured, seven-step decision-making pathway for pharmaceutical professionals selecting elastomeric stoppers, plungers, and combiseals for vials, syringes, and cartridges.

The acronym covers:

Particulate (contamination sources, size categorization, and detection methods per USP <788>/<789>)
Extractables & Leachables (E&L migration risk, coating strategies, and patient population considerations)
Regulatory (global enforcement and standards mapping across FDA, EMA, NMPA, and other authorities)
Functionality (break-loose force, glide force, self-sealing, multipuncture, and plunger movement during transport)
Engineering Capabilities (fill/finish line compatibility, stickiness, twinning, bulging, and FAT/SAT testing)
Container Closure Integrity (interference fit evaluation, land and valve seal geometry, deterministic vs. probabilistic CCI test methods)
Total Quality (physical dimensions per ISO tolerances, chemical formulation consistency, and biological cleanliness including bioburden and endotoxin limits).

Drawing on Datwyler's proprietary quality data — including a survey showing cellulose accounts for 60.9% of particulate contamination in injectable products — the paper equips drug manufacturers with the knowledge to evaluate suppliers, reduce recall risk, and build regulatory-defensible packaging programs aligned with evolving FDA and EU GMP Annex 1 expectations.

Contamination is the leading cause of drug recalls per FDA recall data, with Datwyler's own quality survey identifying cellulose from paper as responsible for over 60% of particulate contamination in injectable products — making particulate reduction through manufacturing environment design and component selection the single most impactful risk mitigation lever available to drug packaging teams.
Extractables and leachables risk is not a fixed property of a rubber compound but a drug-specific interaction that must be evaluated for every unique drug-component combination, with dosing frequency, route of administration, and patient population all influencing the acceptable leachables threshold — considerations that guide Datwyler's compound and coating recommendations.
Datwyler's P.E.R.F.E.C.T. framework gives pharmaceutical packaging teams a comprehensive, regulatory-aligned checklist spanning seven critical evaluation criteria — from CCI interference fit geometry and fill/finish machinability to USP and EP compliance — helping manufacturers select components with confidence and build audit-ready documentation for FDA, EMA, and other global regulatory bodies.

Access This Resource